drugset / Trial / NCT06667154
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.
Timeline
- Start
- 2023-10-10
- Primary completion
- 2025-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 0.3 mg/kg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |